We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-6.58%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.73B
AUM Growth
-$470M
Cap. Flow
-$39.5M
Cap. Flow %
-1.06%
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
23
Closed
9

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$46.8M
2
PEN icon
Penumbra
PEN
+$38.2M
3
BPMC
Blueprint Medicines
BPMC
+$26.6M
4
ABOS icon
Acumen Pharmaceuticals
ABOS
+$17.4M
5
AMGN icon
Amgen
AMGN
+$17M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$44.5M
2
PODD icon
Insulet
PODD
+$40.1M
3
CNMD icon
CONMED
CNMD
+$27.9M
4
ABCM
Abcam PLC
ABCM
+$26M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.04%
2 Consumer Staples 1.17%
3 Industrials 0.83%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$29B
$49.5M 1.33%
279,500
-65,500
-19% -$12.5M
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$49.3M 1.32%
1,131,207
+9,560
+0.9% +$341K
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.81B
$47.5M 1.27%
392,000
-33,000
-8% -$3.73M
EW icon
29
Edwards Lifesciences
EW
$53B
$44.8M 1.2%
647,300
+1,400
+0.2% +$113K
FRPT icon
30
Freshpet
FRPT
$3.26B
$43.6M 1.17%
662,500
– –
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.21B
$40.2M 1.08%
1,178,002
– –
ASND icon
32
Ascendis Pharma A/S
ASND
$16.8B
$39.8M 1.07%
425,500
– –
RYTM icon
33
Rhythm Pharmaceuticals
RYTM
$7.95B
$36.6M 0.98%
1,597,123
– –
PHR icon
34
Phreesia
PHR
$769M
$33.2M 0.89%
1,776,391
+471,391
+36% +$12.7M
IRTC icon
35
iRhythm Holdings
IRTC
$4.1B
$33.1M 0.89%
350,750
+41,300
+13% +$4.2M
PCRX icon
36
Pacira BioSciences
PCRX
$974M
$32.4M 0.87%
1,055,500
+20,500
+2% +$739K
ACCD
37
DELISTED
Accolade Inc
ACCD
$30.8M 0.83%
2,913,000
+93,000
+3% +$1.22M
LEGN icon
38
Legend Biotech
LEGN
$4B
$30.8M 0.82%
458,265
– –
ZLAB icon
39
Zai Lab
ZLAB
$2.65B
$30.1M 0.81%
1,237,023
+14,600
+1% +$389K
PRTA icon
40
Prothena Corp
PRTA
$468M
$29.6M 0.79%
614,298
-139,164
-18% -$8.27M
HZNP
41
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$29.6M 0.79%
255,500
-239,500
-48% -$25.7M
SWAV
42
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$29.4M 0.79%
147,500
+32,400
+28% +$7.66M
ABCM
43
DELISTED
Abcam PLC
ABCM
$28.9M 0.77%
1,275,000
-1,130,000
-47% -$26M
MDGL icon
44
Madrigal Pharmaceuticals
MDGL
$11.9B
$28.7M 0.77%
196,369
-2,849
-1% -$536K
AMLX icon
45
Amylyx Pharmaceuticals
AMLX
$2.53B
$28.3M 0.76%
1,545,016
+400
+0% +$8.46K
ACRS icon
46
Aclaris Therapeutics
ACRS
$867M
$27.1M 0.73%
3,960,449
-1,400
-0% -$12K
DVAX
47
DELISTED
Dynavax Technologies
DVAX
$26.8M 0.72%
1,813,758
– –
XLV icon
48
State Street Health Care Select Sector SPDR ETF
XLV
$44B
$25.7M 0.69%
200,000
– –
LFST icon
49
Lifestance Health
LFST
$4.55B
$25.2M 0.68%
3,670,000
+770,000
+27% +$6.24M
IMVT icon
50
Immunovant
IMVT
$8.24B
$24.7M 0.66%
+644,344
New +$14.6M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rock Springs Capital Management held 129 positions worth $3.73B, down 11% from $4.2B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management's Q3 2023 filing shows 6 new, 41 increased, 23 reduced and 9 closed positions. Its largest new stake was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M. The largest sale was argenx, an estimated $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2023 buy was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2023, an estimated $46.8M increase.
  • Rock Springs Capital Management's biggest Q3 2023 reduction was argenx, cutting an estimated $44.5M.
  • Rock Springs Capital Management fully exited CONMED in Q3 2023, selling an estimated $27.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.73B portfolio in Q3 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 9 in Q3 2023.
  • Rock Springs Capital Management's portfolio value fell 11% quarter-over-quarter to $3.73B.

Based on Rock Springs Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.